Dr. Kunal Saxena - Managing Director of Rusan Pharma Ltd has done his PhD in Pharmacology from the University of Bristol (UK), M.Sc. in Chemistry from Moscow State University (Moscow, Russia) and B.Sc. in Biochemistry from University of Notre Dame (USA). He has done basic research in the area of opioid receptor and developed several novel non-opioid compounds which help reduce side effects and tolerance to opioid analgesics. His work on basic opioid receptor pharmacology has been published in some of the leading journals such as Journal of Molecular Pharmacology (Link), Journal of Neurochemistry (Link), Journal of Biological Chemistry (Link). At Rusan, Dr. Kunal Saxena is responsible for developing the concept of opioid deaddiction treatment in India and internationally. Rusan Pharma is a global pharmaceutical company and are one of the few Indian companies that offer a one-stop-shop solution for treating various forms of addictions such as drugs, alcohol and smoking. Rusan has been in the fore-front of making Opioid Substitution Treatment (OST) an acceptable form of treatment in India. Rusan has been working closely with various NGOs, doctors, hospitals, clinics and NACO for scaling up the OST in India.

pharmaceutical